PrimeCryptoInvest
About PrimeCryptoInvest
PrimeCryptoInvest is a reputable company specializing in global fund management services. It operates under the legal framework of the United Kingdom with registration license SIC 64205. The official platform can be accessed at primecryptoinvest.uk.
Registration and Contact Information
PrimeCryptoInvest’s registered address is 24 Spring Street Paddington, London, W2 3RA, United Kingdom.
Contact phone: +44 (745)127-2984 (Monday-Friday).
Email: admin@primecryptoinvest.uk and support@primecryptoinvest.uk.
Investment Programs
PrimeCryptoInvest presents clients with a choice among four distinctive investment plans:
- trial starting from $100,
- standard starting from $1600,
- gold starting from $6100,
- unlimited starting from $17100.
Each deposit is treated as an individual investment.
Referral Program
The company extends an invitation to participate in its referral program without the necessity of an active deposit. Users have the opportunity to attract new participants and generate additional earnings.
Registration and Login to Personal Account
Registration entails providing a name, login details, email address, setting up a secret question and answer, and agreeing to the Terms and Conditions. Upon registration, users gain access to their personal account to manage deposits and request withdrawals.
Deposit and Withdrawal of Funds
Account funding and profit withdrawals can be facilitated through payment systems like PerfectMoney, Bitcoin, Payeer, ETH, LTC, DOGE, BCH. Transaction fees are determined by the respective payment system. The minimum withdrawal amount is $0.8, or $3 for cryptocurrency. Requests are typically processed within 48 hours.
Conclusion
PrimeCryptoInvest’s website offers limited information concerning the project, lacking details about its leadership and creators, as well as collaboration terms. It is recommended to peruse reviews on brokertribunal.com before considering any form of collaboration.
This review has been prepared by the specialists at ExpertsReview.